gastrointestinal stromal tumors

Conference Insider

Selinexor+Imatinib Combo Found Well Tolerated in IM-Resistant Advanced GIST

06/15/2021

Results following the phase Ib portion in the evaluation of imatinib in combination with selinexor displays well tolerability in patients with imatinib (IM)-resistant, advanced GIST, presented at the 2021 ASCO Annual Meeting.

Results following the phase Ib...

06/15/2021

Oncology

Research in Review

Imatinib Treatment for GISTs Leads to Long-Term Survival in Certain Patients

02/22/2017

JCP Editors

Imatinib mesylate front-line treatment of advanced or metastatic gastrointestinal stromal tumors (GISTs) leads to significant long-term survival in patients with a specific genetic mutation, according to study...

...

02/22/2017

Journal of Clinical Pathways

Research in Review

Most Cost-Effective Sequence of TKIs for Treatment of GISTs Identified

01/10/2017

JCP Editors

The best potential strategy involving tyrosine kinase inhibitors (TKIs) for the treatment of gastrointestinal stromal tumors (GISTs) has been identified, according to new research published in Clinical Drug...

The...

01/10/2017

Journal of Clinical Pathways